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Abstract - Basing on the current knowledge, this paper is 
aimed to review the core characteristics of the most relevant 
therapeutic agents (steroids and antihistamines), 
administered to prevent perioperative anaphylaxis. 
Moreover, the Authors propose the validation of a Global 
Anaphylactic Risk Score, built up by recording the 
individual scores related to the most relevant anaphylaxis 
parameters (i.e. medical history, symptoms and medication 
for asthma, rhinitis and urticaria etc) and by adding them 
on all together; the score could be used in the preoperative 
phase to evaluate the global anaphylactic risk and to 
prescribe risk-oriented premedication protocols. 
 





 More and more, the allergologists have been 
involved, together with the anaesthesiologists, in the 
perioperative anaphylactic risk evaluation and decision 
making about which premedication drugs should be 
prescribed. These decisions are difficult because of the 
intrinsic complexity of diagnostic procedures and the 
frequent comorbidities (i.e. diabetes, arterial and/or ocular 
hypertension, cerebral angiomas, immune deficiencies, 
etc) and the poor diffusion of guidelines. Consequently 
we propose a tool to evaluate Global Anaphylactic Risk 
Score that is aimed to: 1) to ensure a correct diagnostic 
and patient-oriented therapeutic procedure; 2) to attain an 
elevate level of procedures standardization, in order to 
avoid personalized therapeutic drifts; 3) to optimize 
recovery times in the case of adverse reactions; 4) to 
reduce legal problems related to incorrect therapeutic 
procedures for the patient's recovery. Anaphylaxis is the 
heaviest generalized immediate hypersensitivity reaction, 
potentially life-threatening, marked by the release of 
multiple chemical mediators and cytokines, having 
multiple effects on metabolism, cardiovascular and 
respiratory systems and virtually all organs. Although it 
was firstly described one hundred years ago, until now the 
agreement about its definition and diagnostic criteria has 
not been reached. Nowadays, the term of “anaphylactoid 
reaction” has been abandoned and all the generalized 
reactions are classified as anaphylaxis; the latest 
document of World Allergy Organization [1] 
distinguishes the following pathogenic mechanisms of 
anaphylaxis: 
Immunologic 
1. IgE mediated (Type-I of Gell and Coombs 
classification) i.e. foods, drugs, hymenoptera venom, 
etc. 
2. Not IgE-mediated (involvement of IgG and/or 
complement) (Type II, mediated by antibodies and/or 
complement, and III, by immune complexes); i.e. 
radio contrast agents, biological agents, blood 
products, drugs. 
Not Immunologic: due to direct mast cells activation 
(because of physical causes: exercise, cold temperature, or 
ethyl alcohol and others drugs) 
Idiopathic: mast cells clonal disorders, unknown causes. 
The prevalence of perioperative anaphylactic reactions, 
IgE or not-IgE mediated, has increased in the last decades 
because of the wide diffusion of surgical procedures; 
these reactions can be due to Anaesthetics, Muscle 
Relaxant, Hypnotics or Latex. Notwithstanding the large 
differences in epidemiologic studies, it can be assumed 
that the prevalence of perioperative anaphylactic reactions 
is about 1/13000 anaesthesia procedures globally 
considered (local, regional, general anaesthesia). The 
mortality attributed to perioperative anaphylaxis ranges 
from 3,5 to 9 % [2]. As muscle relaxants are concerned, 
succinilcolyne, rocuronium, atracurium, vecuronium, 
pancuronium, mivacurium and cisatracurium are the main 
responsible agents for anaphylactic reactions. Curarics [3] 
have the highest anaphylactic reactions rate (50-75% out 
of all reactions); this is caused by the high content in 
quaternarium ammonium ions, acting as antigenic 
determinants able to bind to specific IgE. As to hypnotics, 
both barbiturics (thiopentale) and non barbiturics 
(propofol) may induce hypersensitivity reactions with IgE 
as well as non IgE-mediated mechanism. Anaphylactic 
reactions during general anaesthesia may supervene 
because of IgE-mediated sensitization to ethylene oxyde 
or to plasma expanders (polygelines). Latex might be 
responsible for more than 10% of intraoperative 
anaphylactic reactions because of contact with gloves, 
catheters and endotracheal tubes. 
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PREMEDICATION 
The drugs able to antagonize histamine effects (antiH1, 
antiH2) and those modulating immune system activation 
(steroids) are the most used to prevent the anaphylactic 
reactions induced by anaesthetics. In the latest years many 
different premedication protocols for patients at risk for 
anaphylaxis have been proposed; so far, these protocols 
[4] induce some perplexities because of the side effects of 
high dosage steroids, their lymphocytolytic and 
immunosuppressive effect, the frequent presence of 
comorbidities, and the fact that the same fixed dosage is 
prescribed for all the patients. Various combination of 
anti- H1, anti H2 and glucocorticoids are used with 
different time schedule and way of administration ( per os 
or i.m.).  
 
CORTICOSTEROIDS 
When an antinflammatory or immunosuppressive effect is 
desirable, steroids having low mineralcorticoid and high 
glucocorticoid action, as prednisone, prednisolone, 
methylprednisone, desametasone, betametasone are the 
most used.  
Glucocorticoids (GCs) are potent anti-inflammatory and 
immunosuppressive agents, which exert multiple effects 
on immune cell functions. GCs act through different 
genomic and non-genomic mechanism, mediated by their 
binding to cytosolic glucocorticoid receptor or by 
interacting directly with enzymes and other cell proteins. 
GCs actions can be early or late: their early effect is 
described as “non genomic” and it's limited to very high 
doses administration; the late effects is described as 
“genomic”, it takes more time (it requires longer than 24-
48 hours) in order to realize the link between the drug and 
the cytoplasmic receptor (GREs) and the subsequent 
translocation of the complex steroid-receptor to the 
nucleus; this complex then reacts with specific genomic 
sequences influencing the mRNA transcription encoding 
enzymes inhibiting the synthesis of inflammation 
mediators.  
The latter mechanism requires several hours and then 
cannot be invoked to justify the clinical use of GCs for 
the immediate prophylaxis and treatment of anaphylaxis 
while the non-genomic actions justify the rapidity action 
of GCs administrated in high doses (tab 2). GCs are able 
to interact directly with the cell membrane entering the 
phospholipidic double-layer, altering its properties. This 
effect can also occur in the mitocondria, inducing a proton 
conductance abnormality, which causes a lower 
production of ATP. Another non-genomic mechanism 
consists in the release of heat shock protein (HSP) and 
chaperonins by the GC-GCR complex, leading to release 
of arachidonic acid from membrane phospholipids. GCs 
can bind to another type of receptor for GC expressed on 
the cell membrane (GCm). In recent years, the link 
between GCs and post-transcriptional mechanisms has 
been remarked in many studies. The control of post-
transcriptional pathways could exert rapid anti-
inflammatory actions since post-transcriptional effects 
take few minutes to become evident, as shown on human 
epithelial airway cells [5].  
The link between GCs and post-transcriptional effects can 
be so schematized: 
1. GCs accelerate the mRNA decay of cytokines (IL-6, 
IL-1α, etc.) chemokines and pro-inflammatory 
molecules. 
2. GCRs act as RNA-binding protein. 
For these reasons and by these pathways, GCs can turn-
off the basal activity of some immune system cells before 
genomic effects. 
The genomic action is attained also with lower doses of 
the drug; so far it hasn't been yet established a precise 
dose-response relationship between genomic and non-
genomic action. Anyway it has been pointed out that the 
needed dose to attain a sharp non-genomic effect is higher 
than 100 mg of prednisone or another equivalent 
glucocorticoid. The steroids gained an undoubtedly 
preeminent place in enhancing the bronchial beta2 
receptors sensitivity to beta-agonists, so that they are 
unchangeable drugs to attain asthma control; these effects 
are linked to genomic mechanisms that need the right time 
to switch on. On the other hand, also the inhibition of 
glucocorticoids on a wide range of T and weakly B 
lymphocyte immune responses, as well as the powerful 
suppressive effect on phagocyte functions, require a 
variable latent period related to the intrinsic action 
mechanism. On the contrary, the efficacy of steroids in 
inhibiting the mast cells chemical mediators release is just 
partial; many authors, working on isolated pulmonary, 
intestinal and cutaneous mast cells [6], showed that 
desametasone is not able to inhibit preformed mediators 
release; that's the reason why the steroid efficacy in the 
anaphylaxis treatment is really limited to the late phase 
and doesn't work in the early phase. Moreover, there are 
other in vivo experiences confirming this point of view: 
Naitoh et Al reported that high dose steroid therapy was 
not able to inhibit systemic anaphylaxis after 
cotrimoxazole in a patient suffering from Lupus 
Erythematosus Systemicus [7]. A recently published 
Cochrane systematic review [8] about the use of 
glucocorticoids in the anaphylaxis treatment showed that 
there aren't highly quoted published papers from 1945 till 
today in favour of the glucocorticoids efficacy in the 
emergency treatment of anaphylaxis. 
 
ANTIHISTAMINES 
H-1 antihistamines act as histamine receptor reversible 
antagonists; they are generally well absorbed by 
gastroenteric tract and after oral taking they reach the 
plasmatic concentration peak and start their action in 
average 45-120 min; the pharmacologic effects last from 
4-12 to 24 hours and in the case of particular molecules, a 
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Desloratadine <1 24 no 
Levocetirizine <1 24 no 











Tab 1: antihistamines latency and length of action ( empty cell are in 
case of discordant data) 
 
 
Because of these peculiar characteristics, H1 
antihistamines, alone or in combination with antiH2, have 
been used in many premedication protocols in patients at 
risk of adverse reaction to general anaesthetics. H1 
antihistamine can prevent the oedema due to histamine-
induced capillary hyperpermeability and inhibit 
hyperemia and itch. These drugs inhibit both histamine-
mediated vasoconstriction and partially its early 
vasodilatory effects, mediated by H1 receptors placed on 
endotelial cells. Residual vasodilation is imputable to 
vessel musculature H2 receptors involvement and can be 
inhibited by co-administration of H2 antihistamines. The 
premedication with H1antihistaminees isn't sufficient to 
prevent an adverse reaction [9]; this unmet need has been 
observed both in latex and drugs allergies [10]. The 
inefficacy in preventing  not specific histamine release 
induced bronchospasm and hemodynamic alterations [11], 
together with considerations regarding drugs 
pharmacokinetics, limit the utility of the administration of 
anti H1 before general anaesthesia in patients at risk, 
when this is aimed to reduce or impair possible adverse 
reaction. 
The doubts and uncertainties regarding the efficacy of 
premedication with antihistamines are linked to the 
consideration that there is no certainty that the full 
receptors' saturation can be achieved, particularly at the 
respiratory level, following the doses, ways and drugs 
formulations used; consequently the antihistamine 
premedication should be started at least three days before 
the event, doubling the daily dose and using the last 
generation drugs securing higher action speed and 
reducing the main side effects as sedation. Moreover, we 
can't forget pharmacokinetic and pharmacodynamic 
considerations imposing parenteral administration when 









 We propose a tool to mark some critical parameters 
regarding the preoperative anaphylactic risk. The Global 
Anaphylactic Risk Score (G.A.R.S.) can be represented as 
traffic-light symbol on the basis of colour (the risk can be 
described as white, green, yellow, red, following the 
colour code used in the ER triage, fig.1.) The score sums 
up 8 parameters, obtained from scientific literature and 
openly discussed among the Authors. Other parameters 
may be relevant but a larger study is needed to retrieve 
them properly. In our preliminary example, the 
parameters are multiplied by an arbitrary (that means 
decided by the Authors, basing on their experience and 
needing scientific validation through a focused clinical 
study) correction factor (as shown in the last column, 
figure 2), to attain a global score expressing the 
anaphylactic risk. 
Cardiac ischemia and arrhythmias, i.e. are considered 
severe risk factors because the subsequent hemodynamic 
alterations are able to worsen the clinical outcome of a 
possible anaphylaxis. Moreover the rich mast cells 
representation at cardiac level and arrythmogenic effects 
of the histamine released during allergic reaction justify 
the risk increase in these clinical situations. When drugs 
and/or latex allergy or a documented previous adverse 
reaction to general anaesthetics are reported, an 
allergologist evaluation is strongly advised.  
The systemic mastocytosis requires a separate mention; as 
well known, this diagnosis is based on clinical (peculiar 
skin alterations), hystologic (parenchymal mast cells 
infiltration) and laboratory (blood tryptase increase) 
criteria; mastocytosis affects the anaphylactic risk and its 
therapy must be decided in agreement with onco-
hematologists. 
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III. RISK-ORIENTED PREMEDICATION 
PROTOCOLS FOR SCHEDULED SURGICAL 
PROCEDURES 
 
LOW ANAPHYLACTIC RISK PATIENT: supraglottic 
involvement only (G.A.R.S.<5): STEP 1A 
If the score is equal to or lower than 5, with negative 
medical history (A=0, B=0) and if there are neither any 
uncontrolled asthma's signs (D=0, F=0, G=0), nor 
frequent use of quaternary ammonium containing 
disinfectants (H=0-1), but oculo-rhinitis (C=1-2) and 
occasional assumption of topical drugs, then it could be 
possible, in our projection which needs confirmation from 
focused clinical trial,  to contain the premedication to 
NASAL TOPICAL STEROIDS, per os H1-
ANTIHISTAMINES STARTING 3 DAYS BEFORE 
THE PROCEDURE AND PROMETAZINE OR 
CHLORPHENAMINE MALEATE i.m.1 H. BEFORE 
THE PROCEDURE. 
 
SKIN INVOLVEMENT (G.A.R.S.<10): STEP 1B 
If the score is ranging from 5 to 10, if the patient's history 
is positive for skin involvement and/or occasional adverse 
reactions during previous surgical procedures (A=1x2=2, 
B=1), then it's suitable to add H1 ANTIHISTAMINES 
TO STEP 1 PREMEDICATION, STARTING 1 WEEK 
BEFORE AND PREDNISONE per os 0.5 mg/kg 12 hrs 
AND 2 hrs BEFORE THE PROCEDURE. 
 
MEDIUM ANAPHYLACTIC RISK PATIENT WITH 
MILD AIRWAYS INVOLVEMENT (G.A.R.S.<20): 
STEP 2 
If the attained score is ranging from 10 to 20, i.e. if there 
is positive anamnesis for glottis angioedema (A=2x2=4), 
slight/intermittent uncontrolled asthma's signs, taking into 
account both symptoms and medication score (D=1-
2x2=2-4, F>0, G=1-2), then it could be suitable to add S-
LABA PLUS INHALED STEROIDS, H2- 
ANTIHISTAMINES AND ANTILEUKOTRIENES to 
step 1B premedication, 2 WEEKS BEFORE THE 
PROCEDURE. 
 
HIGH ANAPHYLACTIC RISK PATIENT WITH 
SEVERE AIRWAYS INVOLVEMENT (G.A.R.S. >20): 
STEP 3 
If the patient has positive anamnesis for latex allergy 
and/or adverse reactions in previous surgical procedures 
with high incidence (more than one adverse event out of 
three anaesthesia procedures), and there are severe 
uncontrolled asthma's symptoms (D=3x2=6) and systemic 
anti-allergic drugs frequent use (G=3), it is necessary to 
administrate systemic steroid drugs before the procedure 
to restore sensitivity of bronchial beta receptors to beta-
agonists: add prednisone 0.5 mg/kg per os daily to step 2 
premedication for 2 weeks before the procedure, call the 








 In case of emergency-urgency the proposed 




The most used premedication in allergic patients before 
emergency surgery is: 1 mg/kg prednisone i.v., or its 
equivalent, prometazine i.m. and ranitidine 100 mg i.v. 
(diluted in saline 100 ml) plus s-aba+inhaled steroids 
before the surgical procedure. Nevertheless, the efficacy 
of this premedication protocol is debatable.  
Moreover, the asthmatic patient deserves a close attention 
because she/he's in all probability prone to peri-operative 
broncho-constriction's crises. In case of scheduled 
surgical procedures, asthmatic patients should be admitted 
to previous specialist evaluation [12] at least 1 month 
before the operation, in order to have a congruous time 
frame to reach the best possible clinical asthma control 
[13]. We recommend performing a careful preoperative 
research of signs indicating uncontrolled or badly 
controlled asthma. 
At the same time, we think useful to evaluate pulmonary 
function by O2 saturation (SpO2) and/or arterial blood gas 
analysis, spirometry with flow-volume curve in asthma 
patients.  
Abnormal spirometric data, evaluated out of patient 
clinical context, can't be assumed as absolute 
contraindication to a non-thoracic surgical procedure; 
anyway, as precautionary measure, the minimally 
invasive surgical procedure is preferable when risk is very 
high.  
The preoperative anaphylactic risk's evaluation is a 
complex subject always needing the allergologist 
intervention. This preoperative anaphylactic risk score 
and the related therapeutic interventions step by step, 
represent an orientating tool that can't and must not 
substitute the clinical judgment of the specialist involved 
in the clinical reality with all its unrepeatable peculiarity. 
Moreover, we don't surely expect to include all possible 
clinical contexts, especially before a dedicated trial is 
developed.
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Fig.2. This figure illustrates an attempt to calculate GARS. Risk parameters may be implemented and accuracy of correction factor needs to be tested. 
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1 h before antigen challenge 
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inflammation mediators for 
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